The primary limitation to effective insulin therapy to improve blood sugar control in Type 1 diabetes (T1D) is the risk of hypoglycemia, also known as low blood sugar. Hypoglycemia is considered to be a medical emergency that requires a rapid response to prevent organ and brain damage. This project aims to create the first treatment to restore the body’s ability to counter-regulate insulin-induced hypoglycemia, which would result in better overall health outcomes in the long term for type 1 diabetic patients. The approach is to block somatostatin type 2 (SSTR2) receptors, which is expected to normalize the response of the pancreas to hypoglycemia. The main purpose of the work proposed is to demonstrate safety and efficacy of a candidate molecule to advance toward clinical trials.